Akademska digitalna zbirka SLovenije - logo

Rezultati iskanja

Osnovno iskanje    Ukazno iskanje   

Trenutno NISTE avtorizirani za dostop do e-virov konzorcija SI. Za polni dostop se PRIJAVITE.

1 2 3 4 5
zadetkov: 52
1.
  • Dapagliflozin in Patients w... Dapagliflozin in Patients with Chronic Kidney Disease
    Heerspink, Hiddo J.L; Stefánsson, Bergur V; Correa-Rotter, Ricardo ... The New England journal of medicine, 10/2020, Letnik: 383, Številka: 15
    Journal Article
    Recenzirano
    Odprti dostop

    In this trial, patients with CKD (with or without type 2 diabetes) were randomly assigned to receive dapagliflozin or placebo. The primary composite outcome — a sustained decline in the estimated GFR ...
Celotno besedilo
Dostopno za: CMK, UL

PDF
2.
  • A pre-specified analysis of... A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy
    Wheeler, David C.; Toto, Robert D.; Stefánsson, Bergur V. ... Kidney international, 07/2021, Letnik: 100, Številka: 1
    Journal Article
    Recenzirano
    Odprti dostop

    Immunoglobulin A (IgA) nephropathy is a common form of glomerulonephritis, which despite use of renin-angiotensin-aldosterone-system blockers and immunosuppressants, often progresses to kidney ...
Celotno besedilo
Dostopno za: UL

PDF
3.
  • The dapagliflozin and preve... The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics
    Wheeler, David C; Stefansson, Bergur V; Batiushin, Mikhail ... Nephrology, dialysis, transplantation, 10/2020, Letnik: 35, Številka: 10
    Journal Article
    Recenzirano
    Odprti dostop

    The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the sodium-glucose co-transporter 2 (SGLT2) inhibitor ...
Celotno besedilo
Dostopno za: NUK, UL, UM, UPUK

PDF
4.
  • Effects of Dapagliflozin in... Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease
    Chertow, Glenn M; Vart, Priya; Jongs, Niels ... Journal of the American Society of Nephrology, 09/2021, Letnik: 32, Številka: 9
    Journal Article
    Recenzirano
    Odprti dostop

    In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized, placebo-controlled trial, the sodium-glucose cotransporter 2 inhibitor dapagliflozin ...
Celotno besedilo
Dostopno za: NUK, UL, UM, UPUK

PDF
5.
  • Intradialytic hypotension a... Intradialytic hypotension and risk of cardiovascular disease
    Stefánsson, Bergur V; Brunelli, Steven M; Cabrera, Claudia ... Clinical journal of the American Society of Nephrology, 2014-Dec-05, Letnik: 9, Številka: 12
    Journal Article
    Recenzirano
    Odprti dostop

    Patients undergoing hemodialysis have an elevated risk of cardiovascular disease-related morbidity and mortality compared with the general population. Intradialytic hypotension (IDH) is estimated to ...
Celotno besedilo
Dostopno za: NUK, UL, UM, UPUK

PDF
6.
  • Efficacy and Safety of Dapa... Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial
    Persson, Frederik; Rossing, Peter; Vart, Priya ... Diabetes care, 08/2021, Letnik: 44, Številka: 8
    Journal Article
    Recenzirano
    Odprti dostop

    OBJECTIVE The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) study demonstrated risk reduction for kidney and cardiovascular outcomes with dapagliflozin versus ...
Celotno besedilo
Dostopno za: CMK, NUK, UL, UM, UPUK

PDF
7.
  • Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
    Wheeler, David C; Stefánsson, Bergur V; Jongs, Niels ... The lancet. Diabetes & endocrinology, 01/2021, Letnik: 9, Številka: 1
    Journal Article
    Recenzirano
    Odprti dostop

    Dapagliflozin reduces the risk of kidney failure and heart failure in patients with chronic kidney disease. We aimed to investigate the effects of dapagliflozin on kidney, cardiovascular, and ...
Celotno besedilo
Dostopno za: NUK, OILJ, UL

PDF
8.
  • Effect of Dapagliflozin on ... Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease
    McMurray, John J V; Wheeler, David C; Stefánsson, Bergur V ... Circulation (New York, N.Y.), 02/2021, Letnik: 143, Številka: 5
    Journal Article
    Recenzirano
    Odprti dostop

    Dapagliflozin reduces the risk of end-stage renal disease in patients with chronic kidney disease. We examined the relative risk of cardiovascular and renal events in these patients and the effect of ...
Celotno besedilo
Dostopno za: NUK, UL, UM, UPUK

PDF
9.
  • Safety and efficacy of dapa... Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial
    Wheeler, David C; Jongs, Niels; Stefansson, Bergur V ... Nephrology, dialysis, transplantation, 08/2022, Letnik: 37, Številka: 9
    Journal Article
    Recenzirano
    Odprti dostop

    ABSTRACT Background Despite renin–angiotensin–aldosterone system blockade and immunosuppressive treatment, focal segmental glomerulosclerosis (FSGS) often progresses to kidney failure. The objective ...
Celotno besedilo
Dostopno za: NUK, UL, UM, UPUK

PDF
10.
Celotno besedilo
1 2 3 4 5
zadetkov: 52

Nalaganje filtrov